NMS attended ELRIG Therapeutic Oligonucleotide – Drugging The Undruggable

ELRIG Therapeutic Oligonucleotide – took place last week focused on Oligonucleotide therapies. It was a great occasion for New Modality Support and OligoNova Hub to get an update on the latest oligo developments and I must say it is impressive.

🔸 The choice of great keynotes from Rory Johnson on lncRNA therapeutics for oncology and Shalini Andersson showcasing AstraZeneca´s strategy to enable targeted delivery, I think summarizes best the excellent scope of this event.

🔸 On the note of delivery, Felix Schumacher from Roche – RNA Hub nicely illustrated how interdisciplinary integration is crucial to uncover robust ways forward, which when applied enabled them to uncover paths for targeted delivery to the eye and brain.

🔸 I was also very happy to see updates from the trailblazing work done by Cardior Pharmaceuticals and Thomas Thum (very much looking forward on their clinical update that is around the corner) and HAYA Therapeutics with Samir Ounzain delivering a polished presentation on harnessing the dark genome after recently announcing a successful Serie A funding round.
Furthermore, Ribocure Pharmaceuticals AB and Anders Gabrielsen gave a great talk on the clinical development and challenges of bringing siRNA to the patients.

🔸 Oligotherapeutics are getting to the patients and are showing an increase in commercial interest and robustness. Today, the spotlight is truly in developing novel delivery tropistic chemistries, and cross-functional approaches seem to be the most robust way forward.